IBCL-309: The Frequency of Anticardiolipin Antibodies in Patients with Non-Hodgkin Lymphoma

Abstract

Context: The prevalence of antiphospholipid antibodies in the general population ranges from 1–5% and increases when associated with chronic diseases, including oncological ones. Anticardiolipin antibodies are autoantibodies that mistakenly target the body's own cardiolipins on the outside of cell membranes and platelets. Objective: Case detection of anticardiolipin antibodies (aCL) in patients with non-Hodgkin lymphoma (NHL) in order to identify the likelihood of thrombosis. Materials and Methods: The study included 47 primary patients: 31 with aggressive NHL and 16 with indolent NHL patients being complexly investigated, including the study of antibodies to aCL IgG, IgM, anti-β2-glycoprotein I, and lupus anticoagulant according to age, sex, morphology of NHL, focus of the primary tumor, and stage tumor. The definition of Euro-Phospholipid for anti-phospholipid antibody syndrome has been applied. Results: Forty-seven out of 58 NHL patients hospitalized in the Hematology Department of IMSPIO, Republic of Moldova met the criteria of inclusion in the study. At the first visit, 64,1±1,3 (i-v 37–78) was the average age of patients, the duration of the disease was 4,3 (i-v1–12) months, and 42.5% of patients were women, while 57.5% of patients were men. Anticardiolipin antibodies were found in 7 patients (14.9%), in both sexes (men: 4, women: 3), with a predominance in stage IV of the disease of 83.3%. In 71.4%, the primary tumor focus was detected in the lymph nodes, with predominance in the peripheral lymph nodes (61.5%). Conclusions: Anticardiolipin antibodies were estimated in 14.9% of NHL cases, with the same frequency in gender and mean age of 64.1±1.3 years old. The frequency of anticardiolipin antibodies in stage IV was 83.3%, which was the highest.